- Report
- January 2024
- 200 Pages
Global
From €4031EUR$4,150USD£3,477GBP
- Report
- February 2021
- 360 Pages
United States
From €2331EUR$2,400USD£2,011GBP
- Report
- August 2020
Global
From €5138EUR$5,290USD£4,432GBP
- Report
- January 2022
- 110 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21368EUR$22,000USD£18,433GBP
- Report
- June 2019
- 16 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- June 2019
- 18 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- January 2019
- 717 Pages
Global
From €21368EUR$22,000USD£18,433GBP
- Report
- June 2019
- 15 Pages
Japan
€9713EUR$10,000USD£8,379GBP
- Report
- November 2023
- 35 Pages
Global
From €5653EUR$5,820USD£4,876GBP
The Symtuza market is a subset of the HIV/AIDS drug market, focusing on the development and sale of integrase strand transfer inhibitors (INSTIs). These drugs are used to treat HIV infection, and are designed to block the virus from replicating in the body. Symtuza is the only INSTI that combines four drugs into one pill, making it easier for patients to take their medication. The drug is also designed to be more effective than other INSTIs, as it is able to target multiple strains of HIV.
The Symtuza market is highly competitive, with several major pharmaceutical companies vying for market share. Companies such as Gilead Sciences, ViiV Healthcare, and Merck & Co. are all major players in the Symtuza market, offering their own versions of the drug. Other companies, such as Mylan and Teva Pharmaceuticals, also offer generic versions of the drug. Show Less Read more
